Advertisement

Carbamazepine

  • P. N. Patsalos
Chapter

Abstract

Salicylic acid does not affect the pharmacokinetics of carbamazepine [1].

Keywords

Salicylic Acid Influenza Vaccination Grapefruit Juice Hypericum Perforatum Conflicting Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol. 1979;15:263–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Hansen SB, Dam M, Brandt J, Hvidberg EF, Angelo H, Christensen JM, Lous P. Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurol Scand. 1980;61:357–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Bergendal L, Friberg A, Schaffrath AM, Holmdahl M, Landahl S. The clinical relevance of the interaction between carbamazepine and dextropropoxyphene in elderly patients in Gothenburg, Sweden. Eur J Clin Pharmacol. 1997;53:203–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Yu YL, Huang CY, Chin D, Woo E, Chang CM. Interaction between carbamazepine and dextropropoxyphene. Postgrad Med J. 1986;62:231–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother. 1999;33:218–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Shahzadi A, Javed I, Aslam B, Muhammad F, Asi MR, Ashraf MY, Zia-ur-Rahman. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24:63–8.Google Scholar
  7. 7.
    Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia. 1993;34:161–2.PubMedCrossRefGoogle Scholar
  8. 8.
    Yasui N, Otani K, Kaneko S, Shimoyama R, Ohkubo T, Sugawara K. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin Psychopharmacol. 1997;12:225–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Watkins VS, Polk RE, Stotka JL. Drug interactions of macrolides: emphasis on dirithromycin. Ann Pharmacother. 1997;31:349–56.PubMedGoogle Scholar
  10. 10.
    Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, Perucca E. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol. 1987;24:836–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Barzaghi N, Gatti G, Crema F, Faja A, Monteleone M, Amione C, Leone L, Perucca E. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharmacol Res. 1988;8:101–5.PubMedGoogle Scholar
  12. 12.
    Marsden JR. Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol. 1988;119:403–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Vincon G, Albin H, Demotes-Mainard F, Guyot M, Bistue C, Loiseau P. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol. 1987;32:321–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Patterson BD. Possible interaction between metronidazole and carbamazepine. Ann Pharmacother. 1994;28:1303–4.PubMedGoogle Scholar
  15. 15.
    Couet W, Istin B, Ingrand I, Girault J, Fourtillan JB. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monit. 1990;12:144–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Saint-Salvi B, Tremblay D, Surjus A, Lefebve MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20 (Suppl B):121–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia. 1980;21:489–96.PubMedCrossRefGoogle Scholar
  18. 18.
    Ulivelli M, Rubegni P, Nuti D, Bartalini S, Giannini S, Rossi S. Clinical evidence of fluconazole-induced carbamazepine toxicity. J Neurol. 2004;251:622–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Spina E, Arena S, Scordo MG, Fazio A, Pisan F, Perucca E. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit. 1997;19:535–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Loupi E, Descotes J, Lery N, Evreux JC. Interactions medicamenteuses et miconazole. A propos de 10 observations. Therapie. 1982;37:437–41.PubMedGoogle Scholar
  21. 21.
    Neef C, de Voogd-van der Straaten I. An interaction between ­cytostatic and anticonvulsant drugs. Clin Pharmacol Ther. 1988;43:372–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia. 1995;36:513–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J. 1982;285:261–2.CrossRefGoogle Scholar
  24. 24.
    Block SH. Carbamazepine-isoniazid interaction. Pediatrics. 1982;69:494–5.PubMedGoogle Scholar
  25. 25.
    Desai J. Perspectives on interactions between antiepileptic drugs (AEDs) and antimicrobials. Epilepsia. 2008;49 (Suppl) 6:47–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68:253–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Dalton MJ, Powell R, Messenheimer JA, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Webster LK, Mihaly GW, Jones DB, Smallwood RA, Philips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27:341–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Bottiger Y, Bertilsson L. No effect on plasma carbamazepine concentration with concomitant omeprazole. Drug Investig. 1995;9:180–1.CrossRefGoogle Scholar
  30. 30.
    Naidu MUR, Shoba J, Dixit VK, Kumar TR, Sekhar EC. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Investig. 1994;7:8–12.CrossRefGoogle Scholar
  31. 31.
    Huber R, Bliesath H, Hartmann M, Steinijans VW, Koch H, Mascher H, Wurst W. Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 1998;36:521–4.PubMedGoogle Scholar
  32. 32.
    Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48:948–56.PubMedCrossRefGoogle Scholar
  33. 33.
    Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother. 2006;40:1190–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Garcia AB, Ibarra AL, Etessam JP, Salio AM, Martinez DAP, Diaz RS, Hera MT. Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol. 2000;23:216–8.CrossRefGoogle Scholar
  35. 35.
    Leite SAO, Leite PJM, Rocha GA, Routledge PA, Bittencourt PRM. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52:210–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Shaughnessy AF, Mosley MR. Elevated carbamazepine levels associated with diltiazem use. Neurology. 1992;42:937–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Brodie MJ, Macphee GJA. Carbamazepine neurotoxicity precipitated by diltiazem. Br Med J. 1986;292:1170–1.CrossRefGoogle Scholar
  38. 38.
    Macphee GA, McInnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986;1:700–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Brown RIG, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol. 1997;13:853–4.PubMedGoogle Scholar
  40. 40.
    Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol. 1988;25:229–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Denio L, Drake ME, Pakalnis A. Gemfibrozil-carbamazepine interaction in epileptic patients. Epilepsia. 1988;29:654.Google Scholar
  42. 42.
    Poondru S, Devaraj R, Boinpally RR, Yamsani MR. Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. Pharmacol Res. 2001;43:301–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64:286–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St. John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68:605–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Pitterle ME, Collins DM. Carbamazepine-10,11-epoxide evaluation associated with coadministration of loxitane and amoxapine. Epilepsia. 1998;29:654.Google Scholar
  46. 46.
    Moller SE, Larsen F, Khant AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol. 2001;21:493–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Grimsley SR, Jann MW, Carter JG, D’Mello AP, D’Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50:10–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine and fluvoxamine. Ther Drug Monit. 1993;15:247–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991;84:583–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Ashton AK, Wolin RE. Nefazodone-induced carbamazepine toxicity. Am J Psychiatry. 2001;153:733.Google Scholar
  51. 51.
    Roth L, Bertschy G. Nefazodone may inhibit the metabolism of carbamazepine: three case reports. Eur Psychiatry. 2001;16:320–1.PubMedCrossRefGoogle Scholar
  52. 52.
    Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, Decourt JP. Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol. 2000;20:46–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Andersen BB, Mikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, Lund J, Mengel H. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. 1991;10:201–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57 (Suppl) 1:20–3.PubMedGoogle Scholar
  55. 55.
    Romero AS, Delgado RG, Pena MF. Interaction between trazodone and carbamazepine. Ann Pharmacother. 1999;33:1370.PubMedCrossRefGoogle Scholar
  56. 56.
    Wiklander B, Danjou P, Rolan P, Tamin SK, Toon S. Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine. Eur Neuropsychopharmacol. 1995;6:310–1.CrossRefGoogle Scholar
  57. 57.
    Pisani F, Fazio A, Oteri G, Perucca E, Russo M, Trio R, Pisani B, Di Perri R. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49:1142–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol. 1995;18:233–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10,11-epoxide by quetiapine. Pharmacotherapy. 2002;22:1500–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Mula M, Monaco F. Carbamazepine-risperidone interactions in patients with epilepsy. Clin Neuropharmacol. 2002;25:97–100.PubMedCrossRefGoogle Scholar
  61. 61.
    Spina E, Amendola D’Agostino AM, Ioculano MP, Oteri G, Fazio A, Pisani F. No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide. Ther Drug Monit. 1990;12:511–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9:24–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Krag B, Dam M, Angelo H, Christensen JM. Influence of disulfiram on the serum concentration of carbamazepine in patients with epilepsy. Acta Neurol Scand. 1981;63:395–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Robertson WC. Carbamazepine toxicity after influenza vaccination. Pediatr Neurol. 2003;26:61–3.CrossRefGoogle Scholar
  65. 65.
    Bourgeois BFD, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. Neurology. 1982;32:1122–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Hilgar E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacology. J Clin Psychopharmacol. 2002;22:68–70.CrossRefGoogle Scholar
  67. 67.
    van Wieringen A, Meijer JWA, van Emde Boas W, Vermeij TAC. Pilot study to determine the interaction of oxiracetam with antiepileptics. Clin Pharmacokinet. 1990;18:332–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Kim KA, Oh SO, Park PW, Park JY. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005;61:275–80.PubMedCrossRefGoogle Scholar
  69. 69.
    Hirschfeld S, Jarosinska P. Drug interaction of terfenadine and carbamazepine. Ann Intern Med. 1993;118:907–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Kulkarni C, Vaz J, David J, Joseph T. Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate – a single dose pharmacokinetic study in human volunteers. Indian J Physiol Pharmacol. 1995;39:122–6.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations